ClinicalTrials.gg
CompletedNCT04886999FEELUpdated Mar 27, 2026Results posted

Study in Adult Patients With Moderate to Severe Asthma

A Phase 3 interventional study of Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A) and Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B) in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 10 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
19th of 40
78 · median 67
Started
2022
with 1 other
Phase 3
20 of 40
none open now
Registered
38th of 40
by date
Lead sponsor
12 of 40
Chiesi Farmaceutici S.p.A.

Among the 40 studies testing beclomethasone in Asthma, this one is the 19th largest by enrollment, is one of 2 that started in 2022, is one of 20 in phase 3, and was the 38th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

This study assessed the influence of pink vs. white pressurized metered-dose inhaler (pMDI) actuators on asthma symptoms perception. There was no prespecified primary objective. The following objectives were assessed:

  • Change from baseline in average visual analog scale (VAS) score of the perception of asthma symptoms and burden over the first 7 days and all 14 days in each treatment period (Questions 3-6);
  • Change from baseline in AQLQ score after 14 days of treatment in each period;
  • Summary measures of psychopharmacological aspects (Questions 7-10);
  • Patients' preference and perception of the devices (Questions 11-16);
  • Change from baseline in reliever medication use over 14 days of treatment in each period (Question 2).

For both treatment periods, "baseline" for the questionnaire data was the 14-day period prior to the first treatment period, and for AQLQ was the value recorded at Visit 2.

Read the detailed description

This was a phase IIIb, exploratory, double-blind, randomised, multicentre, psychopharmacological, 2x2 cross-over study in adult subjects with moderate to severe asthma.

A total of 78 randomised subjects in 10 actives centres were involved. The study focused on the psychopharmacological aspects, particularly on the subjects' preference for the device and on the impact of the device's features on subjects' perception of asthma symptoms. Subjects were informed that the study treatments were the same medication they had received before enrolment as maintenance therapy (i.e. Foster® 100/6 µg pMDI), but with differing device characteristics.

The study lasted approximately 6 weeks for each subject and comprised four visits (Visit [V] 1 to V4), including:

  • Two face-to-face clinic visits: V1 (Day 1, screening/randomisation visit) and V4 (Day 43);
  • Two remote video contact visits: V2 (Day 15) and V3 (Day 29).

After signing the ICF, subjects were screened at the investigational site during the screening/randomisation visit (V1). On the same day, and after checking all inclusion and exclusion criteria, eligible subjects were randomised to one of two study treatment sequences and followed the study treatment sequence as follows:

  • From V1 (Day 1), subjects were treated with commercial Foster® 100/6 µg pMDI during the 14-day baseline period;
  • From V2 (Day 15), subjects were instructed to take CHF1535 100/6 µg pMDI via Inhaler A and Inhaler B during two consecutive periods of 14 days each (first and second treatment periods) in a sequential way dictated by the randomisation:

    • Either CHF1535 100/6 µg pMDI with Inhaler A then CHF1535 100/6 µg pMDI with Inhaler B; or
    • CHF1535 100/6 µg pMDI with Inhaler B then CHF1535 100/6 µg pMDI with Inhaler A.

The first treatment period started at V2 (Day 15) and the second treatment period started at V3 (Day 29), with the end of study visit taking place at V4 (Day 43). A window of ±1 day was allowed for the dates of all study visits except V1 (Day 1).

Please note that "Change from baseline in average VAS score perceptions of asthma-over the 14 Days of treatment - Question #3" was reported as PRIMARY ENDPOINT to comply with CT.gov register requirements, but it should be considered as an OTHER PRE-SPECIFIED endpoint like the other endpoint listed.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Pressurised Metered-Dose Inhalers
  • Psychopharmacological
  • Authorized deception
  • Quality of life
  • Adherence
  • CHF1535 100/6 µg pMDI
  • Inhaler A (white actuator)
  • Inhaler B (pink actuator)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject's and/or subject legal representative's written obtained prior to any study related procedure.
  • Age: ≥18 and ≤75 years of age.
  • Established diagnosis of permanent asthma for at least 6 months prior to screening/randomisation visit
  • Subject on maintenance therapy treated by Foster® (CHF1535 100/6 µg pMDI) for at least 6 months prior to screening/randomisation visit
  • Asthma Control Test (ACT) ≥ 20 at screening/randomisation visit.
  • Subject must have a cooperative attitude and the ability to be trained to use correctly the diary and answer the Visual Analogue Scale (VAS)
  • Subject willing and able to download the application on their personal electronic device to fill in the study e-diary.
  • Female subject of non- defined as physiologically incapable of becoming pregnant or female subject + male Partner must be willing to use a highly effective method from the signature of the informed consent and until Visit 4

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating woman
  • History of 'at risk' asthma
  • Recent exacerbation
  • Non-permanent asthma
  • Asthma requiring more than 1 inhaler for maintenance treatment and more than 1 inhaler for reliever treatment.
  • Asthma requiring use of biologics
  • Respiratory disorders
  • Lower tract respiratory infection
  • Current smoker or ex-smoker with a smoking current use/history of ≥ 10 pack-years
  • Cardiovascular diseases
  • Subject with historical or current evidence of uncontrolled concurrent disease such as but not limited to hyperthyroidism, diabetes mellitus or other endocrine disease, haematological disease and disorders
  • Alcohol/drug abuse
  • Participation in an trial within the last 30 days (60 days for biologics) or a more appropriate time as determined by the Investigator
  • to Foster® constituted an exclusion criterion
  • History of to Foster® or any of its components or a history of any other allergy that in the opinion of the Investigator contra-indicated the subject's participation
  • Subject mentally or legally incapacitated or subject accommodated in an establishment as a result of an official or judicial order
  • Blind, colour-blind subject or any other dyschromatopsia
  • Known psychiatric disorders that may have interfered with successful completion of this protocol according to the Investigator's judgment including schizophrenia, bipolar disorders and psychoses.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Sequence Inhaler A - Inhaler B (Period 1)

    Participants in this group first received Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg pressurized metered-dose inhaler (CHF1535 100/6 µg pMDI) using Inhaler A (white actuator) for a 14-day treatment period. They were instructed to take two puffs twice daily (morning and evening), for a total daily dose of 200 µg Beclomethasone dipropionate and 12 µg Formoterol fumarate. The medication was administered as a metered-dose inhalation of a pressurized solution using a standard actuator. After completing the first treatment period, participants switched to Inhaler B (pink actuator) for another 14 days. The dosage and administration remained identical to the first phase: two puffs twice daily for a total daily dose of 200 µg Beclomethasone dipropionate + 12 µg Formoterol fumarate. There was no washout period between treatments, as the crossover design allowed a direct switch from one inhaler to the other without interruption.

    Drug: Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A) · Drug: Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B)

  • Active comparator
    Sequence Inhaler B - Inhaler A (Period 2)

    Participants in this group first received Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg pressurized metered-dose inhaler (CHF1535 100/6 µg pMDI) using Inhaler B (pink actuator) for a 14-day treatment period. They were instructed to take two puffs twice daily (morning and evening), for a total daily dose of 200 µg Beclomethasone dipropionate and 12 µg Formoterol fumarate. The medication was administered as a metered-dose inhalation of a pressurized solution using a standard actuator. After completing the first treatment period, participants switched to Inhaler A (white actuator) for another 14-day treatment period. The dosage and administration remained identical to the first phase: two puffs twice daily for a total daily dose of 200 µg Beclomethasone dipropionate + 12 µg Formoterol fumarate. There was no washout period between treatments, as the crossover design allowed a direct switch from one inhaler to the other without interruption.

    Drug: Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A) · Drug: Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B)

Interventions

  • DrugBeclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A)

    Drug page: Beclomethasone

    Administered via Inhaler A (white actuator) as two puffs twice daily for a total daily dose of 200 µg Beclomethasone dipropionate and 12 µg Formoterol fumarate. Delivered as a pressurized metered-dose inhalation (pMDI) in a randomized, double-blind, crossover study.

    Also known as: CHF1535 100/6 µg pMDI

  • DrugBeclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B)

    Drug page: Beclomethasone

    Administered via Inhaler B (pink actuator) as two puffs twice daily for a total daily dose of 200 µg Beclomethasone dipropionate and 12 µg Formoterol fumarate. Delivered as a pressurized metered-dose inhalation (pMDI) in a randomized, double-blind, crossover study.

    Also known as: CHF1535 100/6 µg pMDI

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #3

    A study-specific questionnaire was developed to evaluate medication use, asthma symptoms, and treatment perception. It consisted of 16 questions, completed by subjects via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). The questionnaire included Visual Analogue Scale (VAS) ratings, numerical responses, and multiple-choice questions, with VAS primarily used to assess symptom perception and psychopharmacological effects. Question #3 (How would you score your asthma symptoms yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), with subjects rating their asthma symptoms from the previous day on a VAS scale from 0=no symptoms to 100=very symptomatic, with lower scores corresponding to better health. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported.

    Time frame: Baseline and Treatment Day 14 within each treatment period

Other outcomes

  1. Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #4

    A study-specific questionnaire was developed to evaluate medication use, asthma symptoms, and treatment perception. It consisted of 16 questions, completed by subjects via an e-Diary. The questionnaire included Visual Analogue Scale (VAS) ratings, numerical responses, and multiple-choice questions, with VAS primarily used to assess symptom perception and psychopharmacological effects. Question #4 (How burdensome was your asthma yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), requiring subjects to rate the burden of their asthma symptoms from the previous day on a VAS scale ranging from 0 to 100, where 0=no burden at all and 100=very burdensome. Lower scores corresponded to better health and lower perceived burden of asthma. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means by treatment are reported with their relative 95% IC.

    Time frame: Baseline and Treatment Day 14 within each treatment period

  2. Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #5

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #5 ("Did your asthma symptoms improve yesterday?") was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), using a VAS scale from 0 to 100 (0 = no improvement; 100 = maximum improvement), where higher scores indicated better health.The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported with their 95% IC.

    Time frame: Baseline and Treatment Day 14 within each treatment period

  3. Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #6

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #6 ("Did your asthma symptoms worsen yesterday?") was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), using a VAS scale from 0 to 100 (0 = no worsening; 100 = maximum worsening), where lower scores indicated better health. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported with their relative 95% IC.

    Time frame: Baseline and Treatment Day 14 within each treatment period

  4. Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #3

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptoms were assessed using a VAS, ranging from 0=no symptoms to 100=very severe symptoms. Question #3 (How would you score your asthma symptoms yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43). First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. Change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment. Adjusted means reported with their 95%IC.

    Time frame: Baseline and Treatment Day 7 within each treatment period

  5. Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #4

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma burden was assessed using a Visual Analogue Scale (VAS) ranging from 0=no burden to 100=very burdensome condition. Lower scores corresponded to better health. Question #4 (How burdensome was your asthma yesterday?) was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period = average of the VAS scores collected over the first week of treatment within each period. Here the change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment.

    Time frame: Baseline and Treatment Day 7 within each treatment period

  6. Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #5

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0 to 100, where 0 indicated no improvement at all and 100 indicated maximum improvement. Question #5 ("Did your asthma symptoms improve yesterday?") was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. The change from baseline was calculated as the difference between the average VAS score. Adjusted means are reported with their 95%IC

    Time frame: Baseline and Treatment Day 7 within each treatment period

  7. Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #6

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptom worsening was assessed using a VAS, ranging from 0=no worsening at all to 100= maximum worsening. Question #6 (Did your asthma symptoms worsen yesterday?) was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. The change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment. Adjusted means are reported.

    Time frame: Baseline and Treatment Day 7 within each treatment period

  8. Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #7

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #7 (Do you expect any improvement in asthma symptoms with this treatment?) was recorded at V2 (Day 15) and V3 (Day 29), before starting each treatment period. Expected asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0=no expected improvement to 100=maximum expected improvement. Higher scores corresponded to greater expectations of benefit.Summary measures for this question were presented separately as descriptive statistics for the ITT population.

    Time frame: Baseline - V2 (Day 15)

  9. Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #8

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #8 (Do you expect any worsening of your asthma symptoms with this treatment?) was recorded at V2 (Day 15) and V3 (Day 29), before starting each treatment period. Expected asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0=none to 100=maximum worsening. Lower scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.

    Time frame: Baseline - V2 (Day 15)

  10. Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #9

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #9 ("How much do you think this treatment improved your overall asthma symptoms?") was recorded at V3 (Day 29) and V4 (Day 43), after each treatment period. Perceived improvement in overall asthma symptoms was assessed using a Visual Analogue Scale (VAS) ranging from 0 = none to 100 = maximum improvement. Higher scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.

    Time frame: Study Day 14 of each treatment period

  11. Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #10

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #10 ("How much do you think this treatment worsened your overall asthma symptoms?") was recorded at V3 (Day 29) and V4 (Day 43), after each treatment period. Perceived worsening of overall asthma symptoms was assessed using a Visual Analogue Scale (VAS) ranging from 0 = none to 100 = maximum worsening. Lower scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.

    Time frame: Study Day 14 of each treatment period (V3 - Day 29 for Period 1 and V4 - Day 43 Period 2)

  12. Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #11

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions was completed via an e-Diary. Questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' visual preference for the inhalers was assessed through Question #11 ("Which inhaler did you visually prefer?"). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or No preference. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.

    Time frame: Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)

  13. Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #12

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' preference for inhaler use was assessed through Question #12 ("Which inhaler did you prefer to use?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or No preference. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.

    Time frame: Day 43 (V4, i.e.at the end of the entire treatment period during the Exit Interview)

  14. Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #13

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of changes in the inhalers was assessed through Question #13 ("Do you think that changes were made to the inhalers?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.

    Time frame: Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)

  15. Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #14

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of the impact of inhaler changes on asthma symptoms was assessed through Question #14 ("Do you think that changes made across the inhalers have impacted your asthma symptoms?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and % of subjects selecting one of the options was summarized separately for the ITT population by treatment group.

    Time frame: Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)

  16. Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #15

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of asthma symptoms after receiving information about the inhalers was assessed through Question #15 ("Based on the information you have received, did it impact your perception of your asthma symptoms?"), which was answered only at V4 (Day 43), after revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and % of subjects selecting one of the options was summarized separately for the ITT population by treatment group.

    Time frame: Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)

  17. Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #16

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of which inhaler had the biggest impact on their asthma symptoms was assessed through Question #16 ("Which of Inhaler A or Inhaler B had the biggest impact on the perception of your asthma symptoms?"), which was answered only at V4 (Day 43), after revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or I don't know. The number and % of subjects selecting one of the 3 options was reported separately by treatment group.

    Time frame: Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)

  18. Change From Baseline in Average Reliever Medication Use - Over the Entire 14-day Treatment - Question #2

    A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while others were answered at specific study visit timepoints. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Rescue medication use was assessed through Question #2 (How many puffs of rescue medication have you taken yesterday?), answered daily every morning throughout the entire 14-day treatment period, from the day after V1 (Day 2) to the end of the study at V4 (Day 43). The average number of puffs per day was calculated for both the baseline and treatment periods, and the change from baseline was summarized separately for the ITT population by treatment group. Average value for each treatment period = mean number of puffs per day collected over Study Day 1 to Study Day 14 of each treatment period.

    Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 for Period 2)

  19. Change From Baseline in AQLQ Activity Limitation Score - After 14 Days of Treatment

    Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day15) and V3 (Day29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5

    Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)

  20. Change From Baseline in AQLQ Symptoms Score - After 14 Days of Treatment

    Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5

    Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)

  21. Change From Baseline in AQLQ Emotional Function Score - After 14 Days of Treatment

    Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5

    Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)

  22. Change From Baseline in AQLQ Environmental Stimuli Score - After 14 Days of Treatment

    Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5

    Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)

  23. Change From Baseline in AQLQ Overall Score - After 14 Days of Treatment

    Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). Overall score = Σ scores of each 32 domains/ no. of available items in overall AQLQ (0-1)

    Time frame: Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)

  24. Occurrence of Treatment Emergent Adverse Event (TEAEs), Adverse Drug Reactions (ADRs), Severe ADRs, Serious ADRs, Serious TEAEs (Serious Adverse Events), Non-serious TEAEs, Severe TEAEs

    An adverse event (AE) was defined as "any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment". An AE could therefore be any unfavourable and unintended sign (including abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An adverse drug reaction (ADR) was defined as an "untoward and unintended response to an investigational medicinal product related to any dose administered". A serious adverse event (SAE)/serious ADR was defined as any untoward medical occurrence or effect that at any dose: Resulted in death; Was life-threatening; Required hospitalisation or prolongation of existing hospitalisation; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was a medically significant AE.

    Time frame: From V1 (Day 1) to V4 (Day 43)

07

Results

Posted Mar 27, 2026

Participant flow

A total of 81 patients were screened. 78 patients were randomized into two treatment sequences: * 39 received Inhaler A first, then Inhaler B. * 39 received Inhaler B first, then Inhaler A.

Participant flow — Overall Study
MilestoneSequence: Inhaler A - Inhaler BSequence: Inhaler B - Inhaler A
Started3939
Intention-to treat population (itt)3638
Per protocol population (pp)3636
Safety population (saf)3638
Completed3636
Not completed33
Withdrew: Adverse event10
Withdrew: Withdrawal by subject11
Withdrew: Other reason12

Outcome measures

PrimaryChange From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #3

A study-specific questionnaire was developed to evaluate medication use, asthma symptoms, and treatment perception. It consisted of 16 questions, completed by subjects via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). The questionnaire included Visual Analogue Scale (VAS) ratings, numerical responses, and multiple-choice questions, with VAS primarily used to assess symptom perception and psychopharmacological effects. Question #3 (How would you score your asthma symptoms yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), with subjects rating their asthma symptoms from the previous day on a VAS scale from 0=no symptoms to 100=very symptomatic, with lower scores corresponding to better health. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported.

Time frame:
Baseline and Treatment Day 14 within each treatment period
Reported as:
Mean · score on a scale
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #3
score on a scaleInhaler AInhaler B
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #32.68 (0.99 to 4.37)1.63 (-0.06 to 3.32)
Statistical analysis
  • Inhaler A vs Inhaler B · Mixed Models Analysis · p = 0.385 (A linear mixed model for repeat measures was used, including subject, period, treatment, timepoint, period by timepoint interaction and treatment by timepoint interaction as fixed effects.) · Adjusted mean difference: 1.05 · 95% CI -1.34 to 3.45An unstructured covariance matrix within period was assumed, and the Kenward-Roger adjustment was used for the degrees of freedom.
Other pre-specifiedChange From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #4

A study-specific questionnaire was developed to evaluate medication use, asthma symptoms, and treatment perception. It consisted of 16 questions, completed by subjects via an e-Diary. The questionnaire included Visual Analogue Scale (VAS) ratings, numerical responses, and multiple-choice questions, with VAS primarily used to assess symptom perception and psychopharmacological effects. Question #4 (How burdensome was your asthma yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), requiring subjects to rate the burden of their asthma symptoms from the previous day on a VAS scale ranging from 0 to 100, where 0=no burden at all and 100=very burdensome. Lower scores corresponded to better health and lower perceived burden of asthma. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means by treatment are reported with their relative 95% IC.

Time frame:
Baseline and Treatment Day 14 within each treatment period
Reported as:
Mean · score on a scale
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #4
score on a scaleInhaler AInhaler B
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #42.62 (0.58 to 4.65)1.82 (-0.22 to 3.85)
Statistical analysis
  • Inhaler A vs Inhaler B · Mixed Models Analysis · p = 0.582 (A linear mixed model for repeat measures was used, including subject, period, treatment, timepoint, period by timepoint interaction and treatment by timepoint interaction as fixed effects.) · Adjusted mean difference: 0.8 · 95% CI -2.08 to 3.68An unstructured covariance matrix within period was assumed, and the Kenward-Roger adjustment was used for the degrees of freedom.
Other pre-specifiedChange From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #5

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #5 ("Did your asthma symptoms improve yesterday?") was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), using a VAS scale from 0 to 100 (0 = no improvement; 100 = maximum improvement), where higher scores indicated better health.The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported with their 95% IC.

Time frame:
Baseline and Treatment Day 14 within each treatment period
Reported as:
Mean · score on a scale
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #5
score on a scaleInhaler AInhaler B
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #50.25 (-1.27 to 1.76)1.54 (0.02 to 3.05)
Statistical analysis
  • Inhaler A vs Inhaler B · Mixed Models Analysis · p = 0.234 (A linear mixed model for repeat measures was used, including subject, period, treatment, timepoint, period by timepoint interaction and treatment by timepoint interaction as fixed effects.) · Adjusted mean difference: -1.29 · 95% CI -3.43 to 0.85An unstructured covariance matrix within period was assumed, and the Kenward-Roger adjustment was used for the degrees of freedom.
Other pre-specifiedChange From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #6

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #6 ("Did your asthma symptoms worsen yesterday?") was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43), using a VAS scale from 0 to 100 (0 = no worsening; 100 = maximum worsening), where lower scores indicated better health. The overall value for each treatment period was defined as the average of the VAS scores collected over the two weeks of treatment within each period. Adjusted means are reported with their relative 95% IC.

Time frame:
Baseline and Treatment Day 14 within each treatment period
Reported as:
Mean · score on a scale
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #6
score on a scaleInhaler AInhaler B
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #62.53 (0.82 to 4.25)1.66 (-0.05 to 3.38)
Statistical analysis
  • Inhaler A vs Inhaler B · Mixed Models Analysis · p = 0.475 (A linear mixed model for repeat measures was used, including subject, period, treatment, timepoint, period by timepoint interaction and treatment by timepoint interaction as fixed effects.) · Adjusted mean difference: 0.87 · 95% CI -1.55 to 3.3An unstructured covariance matrix within period was assumed, and the Kenward-Roger adjustment was used for the degrees of freedom.
Other pre-specifiedChange From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #3

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptoms were assessed using a VAS, ranging from 0=no symptoms to 100=very severe symptoms. Question #3 (How would you score your asthma symptoms yesterday?) was recorded daily, each morning, from V1 (Day 2) to V4 (Day 43). First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. Change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment. Adjusted means reported with their 95%IC.

Time frame:
Baseline and Treatment Day 7 within each treatment period
Reported as:
Mean · score on a scale
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #3
score on a scaleInhaler AInhaler B
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #32.91 (1.40 to 4.42)1.72 (0.22 to 3.22)
Statistical analysis
  • Inhaler A vs Inhaler B · Mixed Models Analysis · p = 0.267 (A linear mixed model for repeat measures was used, including subject, period, treatment, timepoint, period by timepoint interaction and treatment by timepoint interaction as fixed effects.) · Adjusted mean difference: 1.19 · 95% CI -0.93 to 3.31An unstructured covariance matrix within period was assumed, and the Kenward-Roger adjustment was used for the degrees of freedom.
Other pre-specifiedChange From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #4

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma burden was assessed using a Visual Analogue Scale (VAS) ranging from 0=no burden to 100=very burdensome condition. Lower scores corresponded to better health. Question #4 (How burdensome was your asthma yesterday?) was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period = average of the VAS scores collected over the first week of treatment within each period. Here the change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment.

Time frame:
Baseline and Treatment Day 7 within each treatment period
Reported as:
Mean · score on a scale
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #4
score on a scaleInhaler AInhaler B
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #42.82 (0.88 to 4.77)1.78 (-0.15 to 3.71)
Statistical analysis
  • Inhaler A vs Inhaler B · Mixed Models Analysis · p = 0.45 (A linear mixed model for repeat measures was used, including subject, period, treatment, timepoint, period by timepoint interaction and treatment by timepoint interaction as fixed effects.) · Adjusted mean difference: 1.04 · 95% CI -1.7 to 3.78An unstructured covariance matrix within period was assumed, and the Kenward-Roger adjustment was used for the degrees of freedom.
Other pre-specifiedChange From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #5

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0 to 100, where 0 indicated no improvement at all and 100 indicated maximum improvement. Question #5 ("Did your asthma symptoms improve yesterday?") was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. The change from baseline was calculated as the difference between the average VAS score. Adjusted means are reported with their 95%IC

Time frame:
Baseline and Treatment Day 7 within each treatment period
Reported as:
Mean · score on a scale
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #5
score on a scaleInhaler AInhaler B
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #50.69 (-1.64 to 3.02)1.45 (-0.86 to 3.76)
Statistical analysis
  • Inhaler A vs Inhaler B · Mixed Models Analysis · p = 0.648 (A linear mixed model for repeat measures was used, including subject, period, treatment, timepoint, period by timepoint interaction and treatment by timepoint interaction as fixed effects.) · Adjusted mean difference: -0.76 · 95% CI -4.04 to 2.53An unstructured covariance matrix within period was assumed, and the Kenward-Roger adjustment was used for the degrees of freedom.
Other pre-specifiedChange From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #6

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), others only at V2 (Day 15), V3 (Day 29), and V4 (Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Asthma symptom worsening was assessed using a VAS, ranging from 0=no worsening at all to 100= maximum worsening. Question #6 (Did your asthma symptoms worsen yesterday?) was recorded daily in the morning over the first 7 days of treatment. First week value for each treatment period was defined as the average of the VAS scores that had been collected over the first week of treatment within each period. The change from baseline was calculated as the difference between the average VAS score from baseline (Day 1) and the average VAS score over the first 7 days of treatment. Adjusted means are reported.

Time frame:
Baseline and Treatment Day 7 within each treatment period
Reported as:
Mean · score on a scale
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #6
score on a scaleInhaler AInhaler B
Change From Baseline in Average VAS Score Perceptions of Asthma - Over the First 7 Days of Treatment - Question #62.08 (0.15 to 4.00)1.94 (0.02 to 3.85)
Statistical analysis
  • Inhaler A vs Inhaler B · Mixed Models Analysis · p = 0.919 (A linear mixed model for repeat measures was used, including subject, period, treatment, timepoint, period by timepoint interaction and treatment by timepoint interaction as fixed effects.) · Adjusted mean difference: 0.14 · 95% CI -2.58 to 2.86An unstructured covariance matrix within period was assumed, and the Kenward-Roger adjustment was used for the degrees of freedom.
Other pre-specifiedSummary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #7

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #7 (Do you expect any improvement in asthma symptoms with this treatment?) was recorded at V2 (Day 15) and V3 (Day 29), before starting each treatment period. Expected asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0=no expected improvement to 100=maximum expected improvement. Higher scores corresponded to greater expectations of benefit.Summary measures for this question were presented separately as descriptive statistics for the ITT population.

Time frame:
Baseline - V2 (Day 15)
Reported as:
Mean · score on a scale
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #7
score on a scaleInhaler AInhaler B
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #764.5 ± 34.360.8 ± 36.8
Other pre-specifiedSummary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #8

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #8 (Do you expect any worsening of your asthma symptoms with this treatment?) was recorded at V2 (Day 15) and V3 (Day 29), before starting each treatment period. Expected asthma symptom improvement was assessed using a Visual Analogue Scale (VAS) ranging from 0=none to 100=maximum worsening. Lower scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.

Time frame:
Baseline - V2 (Day 15)
Reported as:
Mean · score on a scale
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #8
score on a scaleInhaler AInhaler B
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #88.9 ± 17.08.0 ± 16.2
Other pre-specifiedSummary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #9

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #9 ("How much do you think this treatment improved your overall asthma symptoms?") was recorded at V3 (Day 29) and V4 (Day 43), after each treatment period. Perceived improvement in overall asthma symptoms was assessed using a Visual Analogue Scale (VAS) ranging from 0 = none to 100 = maximum improvement. Higher scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.

Time frame:
Study Day 14 of each treatment period
Reported as:
Mean · score on a scale
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #9
score on a scaleInhaler AInhaler B
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #941.1 ± 36.544.6 ± 35.8
Other pre-specifiedSummary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #10

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while psychopharmacological questions were answered only at specific study visit timepoints (two questions at V2-Day 15, four at V3-Day 29, and two at V4-Day 43). It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Question #10 ("How much do you think this treatment worsened your overall asthma symptoms?") was recorded at V3 (Day 29) and V4 (Day 43), after each treatment period. Perceived worsening of overall asthma symptoms was assessed using a Visual Analogue Scale (VAS) ranging from 0 = none to 100 = maximum worsening. Lower scores corresponded to better health. Summary measures for this question were presented separately as descriptive statistics for the ITT population.

Time frame:
Study Day 14 of each treatment period (V3 - Day 29 for Period 1 and V4 - Day 43 Period 2)
Reported as:
Mean · score on a scale
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #10
score on a scaleInhaler AInhaler B
Summary Measures for Questions With Continuous Outcomes Covering Subject's Psychopharmacological Aspects - Question #108.0 ± 14.911.8 ± 17.2
Other pre-specifiedCount of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #11

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions was completed via an e-Diary. Questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' visual preference for the inhalers was assessed through Question #11 ("Which inhaler did you visually prefer?"). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or No preference. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.

Time frame:
Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)
Reported as:
Count of participants · Participants
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #11
ParticipantsOverall
Inhaler A14
Inhaler B17
No preference27
Other pre-specifiedCount of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #12

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' preference for inhaler use was assessed through Question #12 ("Which inhaler did you prefer to use?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or No preference. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.

Time frame:
Day 43 (V4, i.e.at the end of the entire treatment period during the Exit Interview)
Reported as:
Count of participants · Participants
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #12
ParticipantsOverall
Inhaler A20
Inhaler B16
No Preference22
Other pre-specifiedCount of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #13

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of changes in the inhalers was assessed through Question #13 ("Do you think that changes were made to the inhalers?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and percentage of subjects selecting one of the three options was summarized separately for the ITT population by treatment group.

Time frame:
Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)
Reported as:
Count of participants · Participants
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #13
ParticipantsOverall
Yes27
No17
I do not know14
Other pre-specifiedCount of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #14

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of the impact of inhaler changes on asthma symptoms was assessed through Question #14 ("Do you think that changes made across the inhalers have impacted your asthma symptoms?"), which was answered only at V4 (Day 43). The question was completed before revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and % of subjects selecting one of the options was summarized separately for the ITT population by treatment group.

Time frame:
Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)
Reported as:
Count of participants · Participants
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #14
ParticipantsOverall
Yes14
No10
I do not know3
Other pre-specifiedCount of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #15

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of asthma symptoms after receiving information about the inhalers was assessed through Question #15 ("Based on the information you have received, did it impact your perception of your asthma symptoms?"), which was answered only at V4 (Day 43), after revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Yes, No, or I don't know. The number and % of subjects selecting one of the options was summarized separately for the ITT population by treatment group.

Time frame:
Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)
Reported as:
Count of participants · Participants
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #15
ParticipantsOverall
Yes12
No39
I do not Know7
Other pre-specifiedCount of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #16

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while questions related to device preference and perception were answered only at V4 (Day 43) during the Exit Interview. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Subjects' perception of which inhaler had the biggest impact on their asthma symptoms was assessed through Question #16 ("Which of Inhaler A or Inhaler B had the biggest impact on the perception of your asthma symptoms?"), which was answered only at V4 (Day 43), after revealing that the only difference between the inhalers was the color of the actuator. Subjects could choose between Inhaler A, Inhaler B, or I don't know. The number and % of subjects selecting one of the 3 options was reported separately by treatment group.

Time frame:
Day 43 (V4, i.e. at the end of the entire treatment period during the Exit Interview)
Reported as:
Count of participants · Participants
Count of Subjects for Questions Covering Subjects' Preference and Perception of the Devices - Question #16
ParticipantsOverall
Inhaler A18
Inhaler B13
No preference27
Other pre-specifiedChange From Baseline in Average Reliever Medication Use - Over the Entire 14-day Treatment - Question #2

A study-specific questionnaire assessed medication use, asthma symptoms, and treatment perception through 16 questions completed via an e-Diary. Some were answered daily from V1 (Day 2) to V4 (Day 43), while others were answered at specific study visit timepoints. It included VAS, numerical, and multiple-choice questions, with VAS used for symptom perception and psychopharmacological effects. Rescue medication use was assessed through Question #2 (How many puffs of rescue medication have you taken yesterday?), answered daily every morning throughout the entire 14-day treatment period, from the day after V1 (Day 2) to the end of the study at V4 (Day 43). The average number of puffs per day was calculated for both the baseline and treatment periods, and the change from baseline was summarized separately for the ITT population by treatment group. Average value for each treatment period = mean number of puffs per day collected over Study Day 1 to Study Day 14 of each treatment period.

Time frame:
Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 for Period 2)
Reported as:
Mean · puffs/day
Change From Baseline in Average Reliever Medication Use - Over the Entire 14-day Treatment - Question #2
puffs/dayInhaler AInhaler B
Change From Baseline in Average Reliever Medication Use - Over the Entire 14-day Treatment - Question #2-0.06 ± 0.69-0.04 ± 0.74
Other pre-specifiedChange From Baseline in AQLQ Activity Limitation Score - After 14 Days of Treatment

Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day15) and V3 (Day29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5

Time frame:
Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)
Reported as:
Mean · score on a scale
Change From Baseline in AQLQ Activity Limitation Score - After 14 Days of Treatment
score on a scaleInhaler AInhaler B
Change From Baseline in AQLQ Activity Limitation Score - After 14 Days of Treatment0.10 ± 0.410.04 ± 0.53
Other pre-specifiedChange From Baseline in AQLQ Symptoms Score - After 14 Days of Treatment

Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5

Time frame:
Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)
Reported as:
Mean · score on a scale
Change From Baseline in AQLQ Symptoms Score - After 14 Days of Treatment
score on a scaleInhaler AInhaler B
Change From Baseline in AQLQ Symptoms Score - After 14 Days of Treatment-0.03 ± 0.420.00 ± 0.66
Other pre-specifiedChange From Baseline in AQLQ Emotional Function Score - After 14 Days of Treatment

Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5

Time frame:
Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)
Reported as:
Mean · score on a scale
Change From Baseline in AQLQ Emotional Function Score - After 14 Days of Treatment
score on a scaleInhaler AInhaler B
Change From Baseline in AQLQ Emotional Function Score - After 14 Days of Treatment0.06 ± 0.370.04 ± 0.71
Other pre-specifiedChange From Baseline in AQLQ Environmental Stimuli Score - After 14 Days of Treatment

Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). The AQLQ scores were calculated as follows: Domain score = Σ scores for all items in the domain / no. of available items in that domain (0-1) AQLQ response was considered: * improved: change in score\>=0.5 * worsened: change in score\<=0.5 * no change: -0.5\<change score\<0.5

Time frame:
Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)
Reported as:
Mean · score on a scale
Change From Baseline in AQLQ Environmental Stimuli Score - After 14 Days of Treatment
score on a scaleInhaler AInhaler B
Change From Baseline in AQLQ Environmental Stimuli Score - After 14 Days of Treatment0.11 ± 0.700.13 ± 0.61
Other pre-specifiedChange From Baseline in AQLQ Overall Score - After 14 Days of Treatment

Asthma Quality of Life Questionnaire (AQLQ), a fully validated disease-specific tool designed to assess physical and emotional impact of asthma in adults. AQLQ consists of 32 questions divided into 4 domains: * Symptoms * Activity Limitation * Emotional Function * Environmental Stimuli Subjects were asked to respond on their condition over the previous 2 weeks via a 7-point scale, (7=not impaired at all; 1=severely impaired; higher score, better quality of life). AQLQ was administered at V2 (Day 15) and V3 (Day 29) via remote video calls, and V4 (Day43) via a face-to-face visit. The baseline value was defined as the last available score collected at the baseline period end (V2, Day15). Overall score = Σ scores of each 32 domains/ no. of available items in overall AQLQ (0-1)

Time frame:
Baseline and Study Day 14 of each treatment period (to Day 29 for Period 1 and to Day 43 Period 2)
Reported as:
Mean · score on a scale
Change From Baseline in AQLQ Overall Score - After 14 Days of Treatment
score on a scaleInhaler AInhaler B
Change From Baseline in AQLQ Overall Score - After 14 Days of Treatment0.05 ± 0.370.04 ± 0.53
Statistical analysis
  • Inhaler A vs Inhaler B · ANOVA · p = 0.823 (Change from baseline in the Standardised Asthma QoL Questionnaire score after 14 days of treatment in each treatment periods was analysed by an analysis of variance (ANOVA) model including treatment, period and subject as fixed effects.) · Adjusted mean difference: 0.01 · 95% CI -0.1 to 0.12
Other pre-specifiedOccurrence of Treatment Emergent Adverse Event (TEAEs), Adverse Drug Reactions (ADRs), Severe ADRs, Serious ADRs, Serious TEAEs (Serious Adverse Events), Non-serious TEAEs, Severe TEAEs

An adverse event (AE) was defined as "any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment". An AE could therefore be any unfavourable and unintended sign (including abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An adverse drug reaction (ADR) was defined as an "untoward and unintended response to an investigational medicinal product related to any dose administered". A serious adverse event (SAE)/serious ADR was defined as any untoward medical occurrence or effect that at any dose: Resulted in death; Was life-threatening; Required hospitalisation or prolongation of existing hospitalisation; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was a medically significant AE.

Time frame:
From V1 (Day 1) to V4 (Day 43)
Reported as:
Count of participants · Participants
Occurrence of Treatment Emergent Adverse Event (TEAEs), Adverse Drug Reactions (ADRs), Severe ADRs, Serious ADRs, Serious TEAEs (Serious Adverse Events), Non-serious TEAEs, Severe TEAEs
ParticipantsInhaler A - SAF PopulationInhaler B - SAF PopulationOverall
TEAE7611
Serious TEAE000
Non-serious TEAE7611
ADR123
Serious ADR000
Severe ADR000
Severe TEAE000
TEAE leading to discontinuation of study treatment000
TEAE leading to death000

Adverse events

Collected over Throughout the study, from Visit 1 (Day 1 - study screening and along the baseline period [Day 1- Day 14]) until Visit 4 (Day 43 ± 1 day, i.e. the end of the second treatment period).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaler A - SAF Population0/72 (0%)0/72 (0%)7/72 (9.7%)
Inhaler B - SAF Population0/74 (0%)0/74 (0%)6/74 (8.1%)
Overall0/74 (0%)0/74 (0%)11/74 (14.9%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventInhaler A - SAF PopulationInhaler B - SAF PopulationOverall
CoughRespiratory, thoracic and mediastinal disorders0/724/744/74
COVID-19Infections and infestations2/721/743/74
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/722/742/74
Oral discomfortGastrointestinal disorders1/720/741/74
InfluenzaInfections and infestations1/720/741/74
NasopharyngitisInfections and infestations1/720/741/74
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/720/741/74
DysphoniaRespiratory, thoracic and mediastinal disorders1/720/741/74
Throat irritationRespiratory, thoracic and mediastinal disorders1/720/741/74
HypertensionVascular disorders1/720/741/74

Baseline characteristics

Intention-to-treat (ITT) set: all randomised subjects who received at least one dose of the study treatment and with at least one available evaluation of efficacy after the baseline. Using this definition, subjects with data just in one treatment period were not taken into account by the statistical models for the calculation of the treatment difference. The ITT set analyses were based on the randomised treatment for each period.

Age, Continuous
Age, Continuous(years)Sequence Inhaler A → Inhaler B (ITT Population) - Period 1Sequence Inhaler B → Inhaler A (ITT Population) - Period 2Total
Mean47 ± 16.251.6 ± 15.249.4 ± 15.7
Sex: Female, Male
Sex: Female, Male(Participants)Sequence Inhaler A → Inhaler B (ITT Population) - Period 1Sequence Inhaler B → Inhaler A (ITT Population) - Period 2Total
Female211940
Male151934
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence Inhaler A → Inhaler B (ITT Population) - Period 1Sequence Inhaler B → Inhaler A (ITT Population) - Period 2Total
White363874
Asian000
Black or African American000
Other000
Region of Enrollment
Region of Enrollment(participants)Sequence Inhaler A → Inhaler B (ITT Population) - Period 1Sequence Inhaler B → Inhaler A (ITT Population) - Period 2Total
Italy363874
08

Study locations

10 sites
  • Chiesi Clinical Trial Site 38011
    Bari, Italy
  • Chiesi Clinical Trial Site 38009
    Battipaglia, Italy
  • Chiesi Clinical Trial Site 38006
    Cagliari, Italy
  • Chiesi Clinical Trial Site 38010
    Catanzaro, Italy
  • Chiesi Clinical Trial Site 38003
    Genova, Italy
  • Chiesi Clinical Trial Site 38001
    Milan, Italy
  • Chiesi Clinical Trial Site 38005
    Naples, Italy
  • Chiesi Clinical Trial Site 38004
    Palermo, Italy
  • Chiesi Clinical Trial Site 38002
    Roma, Italy
  • Chiesi Clinical Trial Site 38007
    Sassari, Italy
09

References and documents

Publications

  • Blasi F, D'Amato M, Patella V, Topole E, Bucchioni E, Martini M, Geraci S, Grapin F, Van der Deijl M, Colloca L. Evaluating the impact of changing inhaler color on perception of symptoms and disease burden in patients with asthma: the FEEL study. J Asthma. 2025 May;62(5):841-849. doi: 10.1080/02770903.2024.2448317. Epub 2025 Jan 17. PubMed 39772981 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Feb 2023, 11 months.

Results were first posted in Mar 2026, 3 years 1 month after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 11 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2021
First posted
May 14, 2021
StartActual
Feb 24, 2022
Primary completionActual
Feb 1, 2023
CompletionActual
Feb 1, 2023
Results first posted
Mar 27, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04886999
Responsible party
Sponsor
First posted
May 14, 2021
Start date
Feb 24, 2022
Primary completion
Feb 1, 2023
Completion
Feb 1, 2023
Results posted
Mar 27, 2026
Last update
Mar 27, 2026

Study contacts

Eva Topole, MD
study director · Chiesi Farmaceutici S.p.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion